Get in Touch

AI powered simulator that predicts probable PICO selections based on your assets intended indication and population description

Book a demo

Unlock the Power of PICO+ for JCA Dossier Planning

As of January 12th, 2025, JCA applies to ATMPs and oncology drugs, with orphan drugs following in 2028 and all remaining therapies by 2030. With JCA and EMA assessments running in parallel, early preparation is more critical than ever. One of the most powerful tools at your disposal? PICO simulation — ensuring your submission is both strategic and aligned with evolving requirements.

PICO+ features

Application of logic, language models and weighted scoring systems
Drug matching against historical HTA assessments, clinical guidelines and trials
Consideration of factors including country preference to determine weighting
Simulates likely scenarios to identify the inputs that will impact outcomes

PICO+ has been specifically developed to save you time and key resources before your JCA submission

Once you have provided key inputs about your therapy and evidence package, PICO+ can assess, reference and swiftly generate a report

Input Data

You send us your asset’s description and intended indication

Data Matching

PICO+ matches inputs against data sets of 500+ drugs/indications from:

 

  • HTA Reports
  • Clinical Guideline
  • Data from clinical trials

PICO Extraction

For matched drugs/indications, PICO+ extracts relevant data from HTA reports and clinical guidelines

Assessment

P4A assess individual PICO components based on returned HTA data and clinical guidelines

Scenario analysis

PICO+ conducts scenario analysis for different PICOs identified and the rationale for their inclusion

Report & Validation

We generate a report that includes details on the methodology, individual PICO components identified, the rationale for their inclusion and the source of the data which can be internally and/or externally validated by industry experts

PICO+ provides tailored models to meet your specific needs

Options range from a 2-day turnaround to a bespoke model that includes a user-friendly excel interface.

Single report – P4A led

Multiple reports – P4A led

Bespoke model

Lead time from initiation

Single report - P4A led

  • 2 days

Multiple reports - P4A led

  • 2 days

Bespoke model

  • 2-3 weeks

Output

Single report - P4A led

  • Single PICO report

Multiple reports - P4A led

  • Pre-defined number of PICO reports

Bespoke model

  • A user-friendly Excel model, customized to your specifications for seamless reporting

Bespoke outputs

Single report - P4A led

Multiple reports - P4A led

Bespoke model

Simulation updates

Single report - P4A led

  • Continuous

Multiple reports - P4A led

  • Continuous

Bespoke model

  • Per agreed schedule

Customer time commitment

Single report - P4A led

  • P4A led

Multiple reports - P4A led

  • P4A led

Bespoke model

  • Asset Data Entry for Simulation

Grab the advantage

Get ahead of the game with PICO+

p4a-logo-small-retina-white

We are award winning global experts in access for orphan drugs and Cell and Gene Therapies.

Twitter Instagram Youtube Linkedin

About

Services

Insights

Case Studies

Contact

  • Aramislaan 88,
  • 6213BV Maastricht, Netherlands
  • +31 6 55 88 71 96
  • contact@partners4access.com